Fennec Pharma Cultura de la Empresa

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc) since July 2009 and serves as its President. Mr. Raykov is a General Partner at DCML, a private investment partnership. He served as a General Partner of Alchem Investment Partners from 2006 to 2007, an event driven hedge fund. Mr. Raykov was a Portfolio Manager and Securities Analyst for John A. Levin & Co. Event Driven Fund from 2002 to 2005. Mr. Raykov was a Securities Analyst for the Merger Fund at Tiedemann Investment Group from 1999 to 2002 and an Investment Banking Analyst at Bear Stearns from 1998 to 1999. He served as Chairman of Fennec Pharmaceuticals Inc. from August 2013 to December 9, 2015 and has been its Director since July 2009. He served as an Independent Director at Wesdome Gold Mines Ltd. since August 26, 2013. Mr. Raykov has been an Independent Director at Amarillo Gold Corp. since July 19, 2013. Mr. Raykov Earned a BS in Business Administration from the University of North Carolina at Chapel Hill.

Ms. Anne F. McKay has been Regulatory Consultant at Fennec Pharmaceuticals Inc. (formerly, Adherex Technologies Inc.) since May 2010. Ms. McKay's primary responsibility is to develop and implement Adherex regulatory strategies. She served as Vice President of Regulatory Affairs at Ocera Therapeutics, Inc. since January 2014 until April 28, 2016. She served as Vice President of Regulatory Affairs at Biolex Therapeutics Inc. (formerly, Biolex Inc.) since November 2008. She was responsible for the development and implementation of Biolex's regulatory strategies. Ms. McKay worked as a Consultant with BWA Consulting LLC, providing regulatory and compliance guidance to a number of biotech and pharmaceutical companies. She served as an Executive Vice President - Drug Regulatory Affairs of Triangle Pharmaceuticals Inc., since October 2000, and served as Vice President, Drug Regulatory Affairs from October 1996 to September 2000. Ms. McKay served as the Director of Regulatory Affairs of Medco Research Inc. Ms. McKay served as the Director of Regulatory Affairs, North America, and held various other regulatory positions during a 15-year tenure at Burroughs Wellcome Co. Her department was responsible for providing support for various FDA submissions, including the NDA submissions for AZT and acyclovir. Ms. McKay holds a B.S. in Animal Science from Michigan State University.

Mr. Robert C. Andrade has been the Chief Financial Officer of Fennec Pharmaceuticals Inc. since November 2015. Mr. Andrade served as Chief Financial Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc.) from September 2009 to August 14, 2013 and served as its Vice President since July 2009. Mr. Andrade served as the Principal Accounting Officer at Adherex Technologies Inc. He is a General Partner at DCML, a private investment partnership. He Co-Founded and serves as Manager of DCML LLC. He served as a Portfolio Manager and Securities Analyst at Millennium Partners L.P. from 2006 to 2007. Mr. Andrade was a Securities Analyst for the Event Driven Fund at Caxton Associates LLC from 2003 to 2005. He served as a Private Equity Associate at Trimaran Capital Partners from 2000 to 2003 and as an Investment Banking Analyst at The Bear Stearns Companies LLC from 1997 to 1999. Mr. Andrade worked in The Leveraged Finance Group of CIBC World Markets. Before to CIBC, he worked in the telecommunications, media and technology group at J.P. Morgan. He served as a Director of Adherex Technologies Inc. from July 2009 to August 14, 2013. Mr. Andrade received his B.A. degree and M.A. in Economics from the University of Southern California.